灵长类及人眼组织中视网膜的高效碱基编辑
针对ABCA4基因c.5882G>A突变所致Stargardt病,研究者设计双腺相关病毒载体编码分裂内含肽腺嘌呤碱基编辑器,在人视网膜类器官、iPSC来源视网膜色素上皮细胞及成人视网膜外植体中优化编辑,并在小鼠和雌性非人灵长类体内实现视锥细胞平均75%、RPE细胞平均87%的编辑,人外植体中未检出脱靶编辑。
要点
- 双AAV载体split-intein腺嘌呤碱基编辑器可校正ABCA4 c.5882G>A(p.Gly1961Glu)突变。
- 在雌性非人灵长类体内平均编辑75%视锥细胞和87%RPE细胞。
- 人视网膜外植体和RPE/脉络膜外植体中未检出脱靶编辑。
核心结论
- 该碱基编辑载体在携带突变小鼠和雌性非人灵长类中实现高编辑率,灵长类高编辑率显示有望用于其他可由碱基编辑靶向的眼病。
研究设计与样本
- 研究设计为双腺相关病毒载体编码分裂内含肽腺嘌呤碱基编辑器,在人视网膜类器官、iPSC来源RPE细胞、成人视网膜外植体及RPE/脉络膜外植体中体外优化,并在携带突变小鼠和雌性非人灵长类体内评价。
主要发现
- 在雌性非人灵长类体内平均编辑75%的视锥细胞和87%的RPE细胞。
- 在携带突变小鼠中实现高水平基因校正。
- 在人视网膜外植体和RPE/脉络膜外植体中未检出脱靶编辑。
关键数值与推荐
- 目标突变为ABCA4 c.5882G>A(p.Gly1961Glu)。
- 雌性非人灵长类体内平均编辑75%视锥细胞和87%RPE细胞。
- 人视网膜外植体和RPE/脉络膜外植体中未检出脱靶编辑。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stargardt disease is a currently untreatable, inherited neurodegenerative disease that leads to macular degeneration and blindness due to loss-of-function mutations in the ABCA4 gene. We have designed a dual adeno-associated viral vector encoding a split-intein adenine base editor to correct the most common mutation in ABCA4 (c.5882G>A, p.Gly1961Glu). We optimized ABCA4 base editing in human models, including retinal organoids, induced pluripotent stem cell-derived retinal pigment epithelial (RPE) cells, as well as adult human retinal explants and RPE/choroid explants in vitro. The resulting gene therapy vectors achieved high levels of gene correction in mutation-carrying mice and in female nonhuman primates, with average editing of 75% of cones and 87% of RPE cells in vivo, which has the potential to translate to a clinical benefit. No off-target editing was detectable in human retinal explants and RPE/choroid explants. The high editing rates in primates show promise for efficient gene editing in other ocular diseases that are targetable by base editing.
引用
- Muller A, Sullivan J, Schwarzer W, et al. High-efficiency base editing in the retina in primates and human tissues. Nat Med. 2025. PMID: 39779923. doi:10.1038/s41591-024-03422-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。